Journey Medical Corporation (DERM)
| Market Cap | 144.03M |
| Revenue (ttm) | 61.86M |
| Net Income (ttm) | -11.43M |
| Shares Out | 27.33M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 72.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,666 |
| Open | 5.24 |
| Previous Close | 5.26 |
| Day's Range | 5.21 - 5.39 |
| 52-Week Range | 4.31 - 9.56 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 12.67 (+140.42%) |
| Earnings Date | May 13, 2026 |
About DERM
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se... [Read more]
Financial Performance
In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $12.67, which is an increase of 140.42% from the latest price.
News
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 mill...
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on ...
Journey Medical Earnings Call Transcript: Q4 2025
EMROSI's launch drove 11% revenue growth and improved margins in 2025, with strong prescription uptake and refill rates. Adjusted EBITDA turned positive, and expanding payer coverage is expected to further boost profitability and sales in 2026.
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Appro...
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on sk...
Journey Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw 21% revenue growth, led by Emrosi's strong launch and rapid prescriber adoption. Gross margin improved sequentially, adjusted EBITDA turned positive, and the company expects sustainable EBITDA positivity in Q4 as payer coverage for Emrosi expands.
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call toda...
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid...
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...
Journey Medical Corporation to Participate in October 2025 Investor Conferences
SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on sel...
Journey Medical Corporation to Participate in September 2025 Investor Conferences
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on se...
Journey Medical Transcript: Emerging Growth Conference 85
A dermatology-focused pharmaceutical firm is experiencing rapid growth following the launch of Emrosi, a new oral therapy for rosacea that has shown superior efficacy and safety compared to the market leader. Prescription growth, payer access, and out-licensing deals are driving the company toward profitability in 2025.
Journey Medical Corporation to Present at the Emerging Growth Conference
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily f...
CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.
Journey Medical Earnings Call Transcript: Q2 2025
Q2 2025 net revenue rose to $15M, driven by EMROSI’s strong launch and rapid prescription growth, offsetting Accutane declines. Gross margin improved to 67%, and cash remained stable at $20.3M. Management expects continued EMROSI momentum and margin gains.
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June ...
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide ...
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOT...
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that pri...
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treati...
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Journey Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw a successful EMROSI launch, contributing $2M to $13.1M in net revenue, with gross margin up to 64% and net loss narrowing to $4.1M. Early adoption is strong, payer coverage is expanding, and legacy brands are stabilizing amid competition.
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions ...